AML
Conference Coverage
‘Best’ for most APL patients: Chemo-free regimen
A chemo-free treatment regimen significantly improves survival over chemotherapy in patients with a rare, virulent leukemia, but those 50 and...
Feature
Widespread carboplatin, cisplatin shortages: NCCN survey
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.
Conference Coverage
ASCO honors Hagop Kantarjian, MD, for leukemia research
Noted Lebanese-American oncologist who leads the leukemia department at MD Anderson Cancer Center is to receive a top award at ASCO 2023.
From the Journals
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
From the Journals
AFib risk with cancer drugs underestimated
Many cancer therapies increase the risk of atrial fibrillation, but this is underreported in clinical trials.
From the Journals
Venetoclax shows promise for r/r hairy cell leukemia
Italian study suggests benefits of administering venetoclax for patients with r/r cases of hairy cell leukemia, a rare blood cancer,
From the Journals
Transplant vs. chemo: Similar AML survival rates
New study showed similar survival rates among AML patients treated solely with consolidation chemotherapy and those who received allogenic HCT.
Conference Coverage
‘Astonishing’ results: Skip salvage chemo, proceed to HSCT
New research on treating acute myeloid leukemia suggested that some patients may safely go straight to stem cell transplantation.
Conference Coverage
Global effort needed to widen access to HSCT
Study findings reveal “unacceptably low” access to HSCT in some regions, triggering a call to action.
Conference Coverage
ASH 2022: New clinical data challenge long-held assumptions
Fresh research to be unveiled at the 2022 American Society of Hematology conference seems to overturn conventional wisdom across a range of issues...
News
FDA approves olutasidenib for some AML patients
Olutasidenib has been green-lighted by the FDA for treatment of some patients with acute myeloid leukemia.